ArticleJournal of diabetes and metabolic disorders2020
Gene ontology enrichment analysis of α-amylase inhibitors from
Article in Journal of diabetes and metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Exploring the therapeutic mechanism of potential phytocompounds fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Molecular docking and network pharmacology study on active compounds ofIn silico pharmacology · 2024Article
- Network pharmacology based anti-diabetic attributes of bioactive compounds fromSaudi journal of biological sciences · 2023Article
- Metabolomics and Network Pharmacology in the Exploration of the Multi-Targeted Therapeutic Approach of Traditional Medicinal Plants.Plants (Basel, Switzerland) · 2022Review
- The Antioxidant and Enzyme Inhibitory Potential ofAntioxidants (Basel, Switzerland) · 2022Article
- GLUT-2 mediated glucose uptake analysis ofJournal of diabetes and metabolic disorders · 2022Article
- Anti-diabetic potential of Corn silk (Journal of diabetes and metabolic disorders · 2022Article
- In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.Journal, genetic engineering & biotechnology · 2022Article
- Article
- Gene set enrichment analysis of PPAR-γ regulators fromJournal of diabetes and metabolic disorders · 2021Article
- Beneficial effect ofJournal of diabetes and metabolic disorders · 2021Article
- In silico analysis of phytoconstituents fromIn silico pharmacology · 2021Article
- Identification of α-amylase inhibitors from flavonoid fraction ofIn silico pharmacology · 2021Article
- Identification of PTP1B regulators fromIn silico pharmacology · 2021Article
- Integration of in silico, in vitro and ex vivo pharmacology to decode the anti-diabetic action ofJournal of diabetes and metabolic disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough α-amylase is the choice of target to manage postprandial hyperglycemia, inhibitors of this enzyme may get absorbed into the systemic circulation and modulate proteins involved in the pathogenesis of diabetes mellitus. Hence, the present study aimed to identify α-amylase inhibitors from
methodsα-amylase inhibitory activity of hydroalcoholic extract/fractions (s) and pure compounds from
resultsFraction rich in flavonoids showed the highest α-amylase inhibitory activity with a IC
conclusionsThe α-amylase inhibitors from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.